Medroxyprogestogen enhances apoptosis of SKOV-3 cells via inhibition of the PI3K/Akt signaling pathway

Journal of Biomedical Research

Volumn 27, Issue 1, 2013, Pages 43-50

  Li, Yan ^a   Jiang, Yi ^a   Wana, Yicong ^a   Zhang, Lin ^a   Tang, Weiwei ^a   Ma, Jingjing ^a   Wua, Shan ^a   Cheng, Wenjun ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Apoptosis; Medroxyprogestogen; Ovarian cancer; Phosphorylation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; CASPASE 3; CASPASE 8; GESTAGEN; MEDROXYPROGESTOGEN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAD; PROTEIN BCL 2; PROTEIN KINASE B; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOBLOTTING; OVARIAN CANCER CELL LINE; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

EID: 84878407678     PISSN: 16748301     EISSN: None     Source Type: Journal    
DOI: 10.7555/JBR.27.20120051     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer Statistics 2009. CA Cancer J Clin 2009; 18: 212-8.
2. Ho CM, Chien TY, Shih BY, Huang SH. Evaluation of complete surgical with pelvic and parataortic lymphadenectomy and paclitaxel plus carboplatin chemotherapy for improvement of survival in stage I ovarian clear cell carcinoma. Gynecol Oncol 2003; 88: 394-9.
3. Jensen JT, Speroff L. Health benefits of oral contraceptives. Obstet Gynecol Clin North Am 2002; 27: 705-21.
4. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. Br J Cancer 1995; 71: 1340-2.
5. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk. J Natl Cancer Inst 2002; 94: 32-8.
6. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-37.
7. Datta SR, Ranger AM, Lin MZ, Sturgill JF, Ma YC, Cowan CW, et al. Survival factor-mediated BAD phosphorylation raises the mitochondrial threshold for apoptosis. Dev cell 2002; 3: 631-43.
8. Berqmann A. Survival signaling goes BAD. Dev Cell 2002; 3: 607-8.
9. del Peso L, González-García M, Page C, Herrera R, Nuez G. Interleukin-3-induced phosphorylation of BAD through the protein kinase Akt. Science 1997; 278: 687-9.
10. Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, et al. Akt phosphorylation of BAD couple's survival signals to the cell-intrinsic death machinery. Cell 1997; 91: 231-41.
11. Bonni A, Brunet A, West AE, Datta SR, Takasu MA, Greenberg ME. Cell survival promoted by the Ras-MAPK signaling pathway by transcription-dependent and -independent mechanisms. Science 1999; 286: 1358-62.
12. Yang X, Liu L, Sternberg D, Tang L, Galinsky I, DeAngelo D. The FLT3 Internal tandem duplication mutation prevents apoptosis in interleukin-3-deprived BaF3 cells due to protein kinase A and ribosomal S6 kinase 1-mediated BAD phosphorylation at serine 112. Cancer Res 2005; 65: 7338-47.
13. Datta SR, Katsov A, Hu L. Interleukin-3-induced phos-phorylation of BAD through the protein kinase Akt. Mol Cell 2000; 6: 41-51.
14. Yang E, Zha J, Jockel J, Boise LH, Thompson CB, Korsmeyer SJ. A heterodimeric partner for Bcl-XL and Bcl-2, displaces Bax and promotes cell death. Cell 1995; 80: 285-91.
15. Alessandro R, Kohn EC. Signal transduction targets in invasion. Clin Exp Metastasis 200; 19: 265-73.
16. Sachdev P, Jiang YX, Li W, Miki T, Maruta H, Nur-E-Kamal MS, et al. Differential requirement for rho family GTPases in an oncogenic insulin-like growth factor-I receptor-induced cell transformation. J Biol Chem 2001; 276: 26461-71.
17. Nguyen KT, Wang WJ, Chan JL, Wang LH. Differential requirements of the MAP kinase and PI3 kinase signal-ing pathways in src-versus insulin and IGF-1 receptors-induced growth and transformation of rat intestinal epi-thelial cells. Oncogene 2000; 19: 5385-97.
18. Sachdev LP, Zeng, Wang LH. Distinct role of phosphatidylinositol 3-kinase and rho family GTPases in Vav3-induced cell transformation, cell motility, and morphological changes. J Biol Chem 2002; 277: 17638-48.
19. Nguyen KT, Zong CS, Uttamsingh S, Sachdev P, Bhanot M, Le MT, et al. The role of phosphatidylinositol 3-kinase, rho family GTPases, and STAT3 in ros-induced cell transformation. J Biol Chem 2002; 277: 11107-15.
20. Arboleda MJ, Lyons JF, Kabbinavar FF, Bray MR, Snow BE, Ayala R, et al. Overexpression of AKT2/protein kinase bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells. Cancer Res 2003; 63: 196-206.
21. Brandi R Whitley, Lea M Beaulieu, Jennifer C, Church FC. Phosphatidylinositol 3-kinase/Akt regulates the balance between plasminogen activator inhibitor-1 and urokinase to promote migration of SKOV-3 ovarian cancer cells. Gynecol Oncol 2007; 104: 470-9.
22. Hua K, Feng W, Cao Q, Zhou X, Lu X, Feng Y. Estrogen and progestin regulate metastasis the PI3K/AKT pathway in human ovarian cancer. Int J Oncol 2008; 33: 959-67.
23. Tangjigamol S, Manusircithaya S, Khunnaroung J, Jesa-dapatarakul S, Tanwanich S. expressions of estrogen and progesterone receptors in epithelial ovarian cancer: a clin-icopathologic study. Int Gynecol Cancer 2009; 19: 620-7.
24. Yang XY, Xi MR, Yang KX, Yu H. prognostic value of estrogen receptor and progesterone recepetor status in young Chinses ovarian carcinoma patients. Gynecol Oncol 2009; 113: 99-104.
25. McDonnel AC, Murdoch WJ. High-dose progesterone inhibition of urokinase secretion and invasive activity by SKOV-3 ovarian carcinoma cell: evidence for a receptor independent nongenomic effect on the plasma membrane. J Steroid Biochem Mol Biol 2001; 78: 185-91.
26. Mita MM, Mita A, Rowinsky EK. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin Breast Cancer 2003; 4: 126-37.
27. Raymond E, Alexandre J, Faivre S, Vera K, Materman E, Boni J, et al. Safety and pharmacokinetics of esca-lated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 2004; 22: 2336-47.
28. Atkins MB, Hidalgo M, Stadler WM, Logan TF, Dutcher JP, Hudes GR, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004; 22: 909-18.
29. Cotter TG. Apoptosis and cancer: the genesis of a research field. Nat Rev Cancer 2009; 9: 501-7.
30. Arafa el-SA, Zhu Q, Barakat BM, Wani G, Zhao Q, El-Mahdy MA, et al. Tangeretin Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Down-regulation of Phosphoinositide 3-Kinase/Akt Signaling Pathway. Cancer Res 2009; 69: 105-8.